AIA Group Ltd Trims Holdings in Illumina, Inc. (NASDAQ:ILMN)

AIA Group Ltd lessened its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 61,280 shares of the life sciences company’s stock after selling 3,934 shares during the quarter. AIA Group Ltd’s holdings in Illumina were worth $8,189,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Cerity Partners LLC increased its position in shares of Illumina by 172.2% during the third quarter. Cerity Partners LLC now owns 24,076 shares of the life sciences company’s stock valued at $3,140,000 after buying an additional 15,231 shares during the period. Private Trust Co. NA grew its holdings in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after acquiring an additional 212 shares during the period. FMR LLC raised its position in shares of Illumina by 127.3% in the 3rd quarter. FMR LLC now owns 767,294 shares of the life sciences company’s stock worth $100,063,000 after acquiring an additional 429,723 shares in the last quarter. Townsquare Capital LLC boosted its position in shares of Illumina by 28.1% during the third quarter. Townsquare Capital LLC now owns 13,109 shares of the life sciences company’s stock valued at $1,710,000 after purchasing an additional 2,872 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Illumina by 1.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 76,579 shares of the life sciences company’s stock worth $9,987,000 after purchasing an additional 1,433 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $80.00 on Monday. Illumina, Inc. has a twelve month low of $79.30 and a twelve month high of $156.66. The stock has a market capitalization of $12.67 billion, a PE ratio of -10.42, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The firm’s 50 day moving average price is $102.80 and its 200-day moving average price is $126.82.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on ILMN shares. Barclays restated an “underweight” rating on shares of Illumina in a report on Tuesday, March 11th. Stephens restated an “overweight” rating and issued a $156.00 price objective on shares of Illumina in a report on Tuesday, March 11th. Guggenheim lowered their target price on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a report on Friday, February 7th. Morgan Stanley cut their price target on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. Finally, Citigroup dropped their target price on Illumina from $130.00 to $90.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $140.90.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.